Amalgamated Bank Trims Stock Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Amalgamated Bank lowered its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 8.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,508 shares of the company’s stock after selling 2,355 shares during the period. Amalgamated Bank’s holdings in Pediatrix Medical Group were worth $185,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after buying an additional 164,333 shares in the last quarter. Boston Partners grew its stake in Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after buying an additional 453,254 shares in the last quarter. Aristides Capital LLC purchased a new position in Pediatrix Medical Group in the 4th quarter worth approximately $246,000. ClariVest Asset Management LLC purchased a new position in Pediatrix Medical Group in the 2nd quarter worth approximately $1,721,000. Finally, Tidal Investments LLC purchased a new position in Pediatrix Medical Group in the 1st quarter worth approximately $442,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th. Truist Financial boosted their price objective on shares of Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price objective for the company in a report on Friday, June 7th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.30.

Pediatrix Medical Group Trading Up 3.0 %

NYSE:MD opened at $11.60 on Tuesday. The company has a fifty day moving average of $10.12 and a 200 day moving average of $8.90. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $13.01. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $976.11 million, a P/E ratio of -13.65, a P/E/G ratio of 1.64 and a beta of 1.56.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The company had revenue of $504.30 million during the quarter, compared to analyst estimates of $505.49 million. During the same period in the prior year, the business posted $0.37 EPS. The firm’s revenue was up .7% compared to the same quarter last year. On average, research analysts predict that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current year.

Insiders Place Their Bets

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO C Marc Richards sold 17,438 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $10.08, for a total transaction of $175,775.04. Following the completion of the transaction, the chief financial officer now owns 175,347 shares of the company’s stock, valued at $1,767,497.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,100 shares of company stock worth $701,889. 2.00% of the stock is currently owned by corporate insiders.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.